Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,474 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,543 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00001813 | Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy | completed | — | 709 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00005927 | Study of Adrenal Gland Tumors | completed | — | 690 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH |
| 1 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT00006421 | Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study | completed | — | 200 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00043472 | Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk | completed | — | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00314119 | Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 | completed | — | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00475761 | Breast Mammogram and Tissue Study | completed | — | 466 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01087294 | Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation | completed | Phase 1 | 85 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01445288 | Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | completed | — | 76 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01563874 | Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins | completed | — | 130 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03030404 | Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer | completed | — | 733 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03734029 | Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | completed | Phase 3 | 557 | Daiichi SankyoINDUSTRY | 20 | Sep 28, 2026 | clinicaltrials |
| NCT04429191 | JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation | completed | Phase 1 | 32 | Jasper Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04573231 | Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer | completed | Phase 2 | 13 | University of Wisconsin, MadisonOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04868149 | Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS | completed | N/A | 20 | The University of Hong KongOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05007106 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 28, 2026 | clinicaltrials |
| NCT05540925 | Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular Carcinoma | completed | — | 3,650 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05712356 | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors(BOLSTER) | completed | Phase 2 | 66 | Lisata Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05753722 | A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | completed | Phase 1 | 79 | Incendia TherapeuticsINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05880160 | Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction(HER-SAFE) | completed | N/A | 90 | University College, LondonOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06396598 | Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer | completed | N/A | 116 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06833658 | Effects of Aromatherapy With Essential Oils on Anxiety and Depression in Perioperative Patients With Pancreatic Cancer | completed | N/A | 156 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07144384 | Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma | completed | Early Phase 1 | 4 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07845266 | Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma | completed | Phase 1 | 13 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01745588 | Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02188745 | ER Reactivation Therapy for Breast Cancer(POLLY) | completed | Phase 2 | 20 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02458014 | Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02619682 | Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02649387 | Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy(MERIT) | completed | Phase 2 | 35 | Mayo ClinicOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03093922 | A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer | completed | Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03349450 | DPX-Survivac and Checkpoint Inhibitor in DLBCL(SPiReL) | completed | Phase 2 | 25 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | completed | Phase 1 / Phase 2 | 219 | CellCentric Ltd.INDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT03643510 | Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer | completed | Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03697577 | CDK and Body Composition Study | completed | — | 30 | Montefiore Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03969706 | Abemaciclib in Patients With Oligodendroglioma | completed | Phase 2 | 10 | Stephen Bagley, MD, MSCEOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04170075 | Whole Body Vibration for the Improvement of Health and Functioning in Participants With Chemotherapy-Induced Peripheral Neuropathy | completed | N/A | 38 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04626479 | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | completed | Phase 1 / Phase 2 | 393 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT04626518 | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | completed | Phase 1 / Phase 2 | 263 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT04945187 | Patient-Reported Outcomes Among Women Wtih Gynecological Cancer (The CONNECT Study) | completed | N/A | 94 | Rigshospitalet, DenmarkOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05077098 | Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer | completed | Phase 1 | 8 | Mark SteinOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05183204 | Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma | completed | Phase 2 | 24 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05269485 | Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 36 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05287113 | Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 176 | Incyte Biosciences International SàrlINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT05498155 | Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer(OlympiaN) | completed | Phase 2 | 50 | AstraZenecaINDUSTRY | 9 | Sep 25, 2026 | clinicaltrials |
| NCT05513742 | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer(COMPANION-003) | completed | Phase 2 | 49 | Compass TherapeuticsINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05607849 | Breast Cancer Screening Uptake: a Randomized Controlled Trial Assessing the Effect of a Decisional Aid(DEDICACES2) | completed | N/A | 20,000 | Nantes University HospitalOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05673057 | Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 80 | Molecular Partners AGINDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT05913713 | HIIT Following Breast Cancer Chemotherapy | completed | N/A | 37 | University of FloridaOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06754085 | Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer | completed | Phase 3 | 131 | HTA Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07024680 | Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC(PRCC) | completed | — | 48 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07295951 | A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia | completed | Phase 1 | 6 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 28, 2026source: clinicaltrials